Sponsor(s):Chinese Anti-Cancer Association
24 issues per year
Current Issue: Issue 10, 2018
Chinese Journal of Clinical Oncology is supervised by China Association for Science and Technology and sponsored by Chinese Anti-Cancer Association. The journal publishes the latest innovative achievements and advanced clinical experience in oncology. The journal aims to serve clinic doctors, technicians and scientific researchers, in promoting the academic exchanges and development and training professionals in the field of oncology. The journal is included in CA, JST and CSCD.
Jiang Guoliang;Gao Guolan
Shou Chengchao;Fang Weigang;Jiang Wenqi;Liu Zhihua;Fan Jia;Yao Zhi;Du Zhi;Wang Ping;Ying Guoguang;Yang Yunhua
Chinese Journal of Clinical Oncology,2018,Vol 45,No. 10
Objective: To analyze the short-and long-term outcomes of elderly patients after esophagectomy by comparing preoperative comorbidities, postoperative complications, and survival rates among different age groups. Methods: We retrospectively reviewed the data of 253 patients who underwent esophagectomy from January to December, 2010 in The First Affiliated Hospital of University of Science and Technology of China. Eighty-eight (34.8%) patients were aged < 60 (group A), 145 (57. 3%) were aged 60–75 (group B), and 20 (7.9%) were aged ≥ 75 (group C). The short-and long-term outcomes of the patients were analyzed. Results: There was significant difference in three group of patients with hypertension before operation (P < 0.05). There was statistically significant difference among all complications, major complications, pulmonary infection, arrhythmia, and respiratory insufficiency (P < 0.05), except for anastomotic leakage and other complications (P > 0.05) among the three groups. The mean follow-up was 50.7 months. The median overall survival and 1-, 3-, and 5-year overall survival rates were 68 months and 98.9%, 86.8%, and 69%, respectively, for group A; 61 months and 93.1%, 76.1%, and 51%, respectively, for group B; and 32 months and 63.3%, 46%, and 28.8%, respectively, for group C (P < 0.001). The median progression-free survival (PFS) and 1-, 3-, and 5-year PFS rates were 60 months and 98.86%, 85.2%, and 45.5%, respectively, for group A; 43 months and 87.6%, 53.1%, and 26.9%, respectively, for group B; and 11 months and 30%, 20%, and 10%, respectively, for group C (P < 0.001). The difference in survival rates between groups A and B, A and C, and B and C was statistically significant (P < 0.001). The multivariate analysis showed that age and TNM stage IV were independent risk factors for overall survival and PFS (P < 0.05). Conclusions: The long-term survival rate decreases significantly in elderly patients with esophageal cancer. In addition, age and advanced pathological stage of tumor are independent risk factors for long-term outcomes.